

Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Karim Sallemi¹

¹ Sapienza University of Rome

Potential competing interests: No potential competing interests to declare.

I find this article extremely useful in clinical practice. it is written in a linear and clean way. The assessment of the patient's economic costs/benefits with the aim of modifying the therapy in a subjective way is certainly a step forward towards personalized medicine. My only question is the following: Could the patient suffer consequences from changing the dosage or even the drug?